VIPoma
VIPoma | |
Pancreatic vipoma. Electron microscopy of a pancreatic VIPoma. Abundant secretory granules of variable size, shape, and density in a pancreatic tumor with WDHA syndrome. Abundant PP-and a few VIP-immunoreactive cells (inset) were detected by light microscopic immunohistochemistry of the same tumor (X28.000). Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology | |
ICD-10 | C25.4 or E16.8 |
ICD-O: | 8155/3 |
DiseasesDB | 13877 |
MedlinePlus | 000228 |
MeSH | D003969 |
For patient information, click here
WikiDoc Resources for VIPoma |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on VIPoma at Clinical Trials.gov Clinical Trials on VIPoma at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on VIPoma
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating VIPoma Risk calculators and risk factors for VIPoma
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
A VIPoma (also known as Verner Morrison syndrome, after the physicians who first described it [1]) is a rare (1 per 10'000'000 per year) endocrine tumor, usually (about 90%) originating in the pancreas, which produces vasoactive intestinal peptide (VIP).
- A syndrome caused by non-β islet-cell tumors.
- It may be associated with multiple endocrine neoplasia.
The massive amounts of VIP in turn cause profound and chronic watery diarrhea and resultant dehydration, hypokalemia, achlorhydria (hence WDHA-syndrome, or pancreatic cholera syndrome), acidosis, vasodilation (flushing and hypotension), hypercalcemia and hyperglycemia.[2]
Symptoms and Signs
The Major clinical features are prolonged watery diarrhea (fasting stool volume > 750 to 1000 mL/day)and symptoms of hypokalemia and dehydration. Half of the patients have relatively constant diarrhea while the rest have alternating periods of severe and moderate diarrhea. One third have diarrhea < 1yr before diagnosis ,but in 25%, diarrhea is present for 5 yr or more before diagnosis. Lethargy, muscle weakness, nausea, vomiting and crampy abdominal pain are frequent symptoms. Hyperkalemia and impaired glucose tolerance occur in < 50% of patients. During attacks of diarrhea, flushing similar to the carcinoid syndrome occur rarely.
Diagnosis
Besides the clinical picture, fasting VIP plasma dosage may confirm the diagnosis, and CT scan and somatostatin receptor scintigraphy are used to localise the tumor, which is usually metastatic at presentation.
Treatment
Besides treating the water and electrolyte abnormalities, octreotide (a somatostatin analogue) can be used to temper symptoms. Surgery is the only curative option.
References
Additional Resources
^The MERCK MANUAL Of Diagnosis And Therapy